Despite the encouraging outcomes of anti-BCMA CAR-T cell therapy in R/R MM, it usually exhibits short-term efficacy and many MM patients still experience disease recurrence or progression. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.